Consensus Evolent Health, Inc.

Equities

EVH

US30050B1017

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
32.79 USD +0.18% Intraday chart for Evolent Health, Inc. +0.58% -0.73%

Evolution of the average Target Price on Evolent Health, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e644b2d9b99082a998d13cf5c.OPVXsxqiVTdnIQAAt-7VtPEafW0asbTA2KKF0XFSWCk.fpQCwXjAMUcIdFV5zYKE4Zk3CAx8w_-jjPXKlBQWNxt0t2b8e5QkbSFOYw~eee3ea50d2477d052a147dfce99bcde8
Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating MT
JPMorgan Trims Price Target on Evolent Health to $52 From $53, Maintains Overweight Rating MT
Canaccord Genuity Cuts Price Target on Evolent Health to $45 From $47, Maintains Buy Rating MT
JMP Securities Initiates Evolent Health With Market Outperform Rating, Price Target is $37 MT
RBC Trims Price Target on Evolent Health to $42 From $44, Keeps Outperform Rating MT
Truist Securities Trims Price Target on Evolent Health to $34 From $36, Maintains Hold Rating MT
UBS Starts Evolent Health With Buy Rating, Price Target is $46 MT
Guggenheim Adjusts Price Target on Evolent Health to $47 From $50, Maintains Buy Rating MT
Stephens Initiates Evolent Health at Overweight With $40 Price Target MT
Cowen Adjusts Price Target on Evolent Health to $59 From $57, Maintains Outperform Rating MT
Cowen Adjusts Evolent Health's Price Target to $57 From $52, Keeps Outperform Rating MT
Truist Securities Starts Evolent Health at Hold With $33 Price Target MT
Canaccord Genuity Cuts Evolent Health's Price Target to $48 From $55, Reiterates Buy Rating MT
BTIG Trims Evolent Health's Price Target to $45 From $55, Keeps Buy Rating MT
JPMorgan Adjusts Evolent Health's Price Target to $52 From $37, Reiterates Overweight Rating MT
RBC Raises Price Target on Evolent Health to $44 From $40, Maintains Outperform Rating MT
BTIG Adjusts Evolent Health's Price Target to $50 From $45, Reiterates Buy Rating MT
Piper Sandler Adjusts Evolent Health's Price Target to $40 From $35, Reiterates Overweight Rating MT
RBC Initiates Evolent Health at Outperform With $40 Price Target, Sees 'Significant Organic Revenue Growth Opportunity' MT
Cowen Raises Evolent Health's Price Target to $50 From $48, Maintains Outperform Rating MT
Piper Sandler Adjusts Evolent Health Price Target to $35 From $37, Maintains Overweight Rating MT
Canaccord Genuity Adjusts Evolent Health's Price Target to $45 from $40, Keeps Buy Rating MT
Piper Sandler Adjusts Evolent Health's Price Target to $37 From $32, Reiterates Overweight Rating MT
Guggenheim Starts Evolent Health at Buy With $43 Price Target MT
BTIG Adjusts Evolent Health's Price Target to $40 From $35, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
32.79 USD
Average target price
45.33 USD
Spread / Average Target
+38.25%
High Price Target
63 USD
Spread / Highest target
+92.13%
Low Price Target
34 USD
Spread / Lowest Target
+3.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Evolent Health, Inc.

Canaccord Genuity
JPMorgan Chase
JMP Securities
RBC Capital Markets
Truist Securities
UBS
Guggenheim
Stephens Inc.
Cowen
Goldman Sachs
Piper Sandler
BTIG
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings